Scarica l'app Stockscreener
1.87
4.47%
0.08
Dopo l'orario di chiusura:
1.88
0.010
+0.53%
Precedente Chiudi:
$1.79
Aprire:
$1.78
Volume 24 ore:
984.61K
Relative Volume:
1.00
Capitalizzazione di mercato:
$143.42M
Reddito:
-
Utile/perdita netta:
$-36.95M
Rapporto P/E:
-2.2262
EPS:
-0.84
Flusso di cassa netto:
$-33.46M
1 W Prestazione:
-16.52%
1M Prestazione:
-0.53%
6M Prestazione:
-72.05%
1 anno Prestazione:
-76.24%
Intervallo 1D:
$1.73
$1.89
Intervallo di 1 settimana:
$1.73
$2.32
Portata 52W:
$1.61
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Confronta LRMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
1.87 | 143.42M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Larimar: Q1 Earnings Snapshot - MySA
Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView
Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX
Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus
Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com
Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan
Larimar Therapeutics awards key executives performance-based stock - MSN
Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX
Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com
Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News
The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com
Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com
Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha
An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com
Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News
Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World
HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World
Larimar Therapeutics Inc (NASDAQ: LRMR) Shares Might Go Down -73.01% This Year - Marketing Sentinel
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World
Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK
Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks
FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia
Larimar: Q4 Earnings Snapshot - mySA
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener
FDA open to new surrogate endpoint for FA drug approval - Investing.com India
Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment - Stock Titan
Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - The AM Reporter
Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World
Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):